CybernaX is a biopharmaceutical company founded by a team of returnees from MIT, Cornell University, University of Toronto, Wuhan University and other well-known research institutions at home and abroad. Based on its own high-throughput screening technology, CybernaX develops more precise, efficient and immunogenicity-controlled drug delivery platforms, and provides competitive products and services around nucleic acid drug development, creating a biopharmaceutical innovation model led by nucleic acid drugs.